ESMO 2026: BXP-001 Plus Radiotherapy Significantly Extends Progression-Free Survival in iNATURE Advanced Tumor Randomized Trial
The iNATURE trial, presented at ESMO 2026, showed that BXP-001 combined with radiotherapy significantly extended progression-free survival in a randomized controlled study of advanced tumors. The trial was co-sponsored by Genvoy Bio/Bay Bio and the University of Hong Kong-Shenzhen Hospital, with the phase 2/3 results presented as rapid oral and poster presentations in Madrid, Spain on October 24, 2026. The original report also claims notable efficacy in post-surgical recurrence prevention, but lists no specific PFS figures, sample size, or hazard ratio.
A phase 2/3 randomized controlled study pairing BXP-001 with radiotherapy and reporting PFS gives concrete context for reading neoantigen vaccine signals.
Source: mp.weixin.qq.com · mp.weixin.qq.com